Roundup litigation: Missouri judge clears $7.25 billion Bayer settlement
The two-decade payout covers current and future non-Hodgkin lymphoma claims, following a Supreme Court ruling that limited state court jurisdiction.
By Harper Foster ·

A Missouri judge approved a settlement Friday that requires agrochemical maker Bayer to pay up to $7.25 billion over the next 20 years. The agreement resolves thousands of claims from U.S. cancer patients who allege the company failed to warn that its weedkiller Roundup could cause lymphoma.
The nationwide deal applies to users who are already ill and those who receive a diagnosis of non-Hodgkin lymphoma in future years. Payouts vary based on usage patterns, age at diagnosis, and illness severity. The average individual payment will range from $10,000 to $165,000.
St. Louis Circuit Judge Timothy Boyer signed the written judgment granting approval. He described the average payouts as "fair and adequate" and called the total dollar amount "among the largest in the history of mass tort personal-injury class action settlements."
Bayer denies that Roundup causes cancer. The settlement offers the German-based company financial certainty against rising litigation costs that previously led it to consider removing the product from U.S. agricultural markets. Bill Anderson, Bayer’s CEO, said the court-approved deal is "a decisive milestone" in the company’s strategy to mitigate risks from pending and future litigation.
The legal landscape shifted in June when the U.S. Supreme Court ruled that Bayer cannot be sued in state courts for failing to warn about cancer. The high court determined that federal regulations do not require a cancer warning label and that states are forbidden from imposing additional labeling requirements. Some attorneys for cancer patients argue the settlement payouts are too small, while others contend the deal is better than getting nothing after the Supreme Court ruling.
Roundup was introduced in 1974 by Monsanto, a Missouri-based company, with glyphosate as its active ingredient. It became a widely used herbicide in agriculture and on residential lawns. Bayer acquired Monsanto in 2018 and inherited the growing number of lawsuits alleging glyphosate causes non-Hodgkin lymphoma. The World Health Organization’s International Agency for Research on Cancer classified the chemical as "probably carcinogenic" in 2015. The U.S. Environmental Protection Agency has determined that the chemical is not likely to cause cancer in humans when used as directed.
Approximately 200,000 Roundup-related claims have been made against Bayer, many from people who used the product on residential lawns and gardens. Bayer has removed glyphosate from new versions of Roundup sold for residential markets. Only a couple of dozen cases have gone to juries, with mixed results. A Georgia jury awarded plaintiffs $2.1 billion in one case. In the first verdict since the Supreme Court ruling, a Missouri jury sided with Bayer in October on claims of design defects, negligence, and fraud. Bill Dodero, Bayer’s U.S. general counsel, said the verdict should send a strong signal that plaintiffs will face challenges in future cases.
The settlement decision may be appealed.
More Business · Watch Your Wallet · Report a business · Got a Story?






